CPT11 with P-glycoprotein/CYP 3A4 dual-function inhibitor by self-nanoemulsifying nanoemulsion combined with gastroretentive technology to enhance the oral bioavailability and therapeutic efficacy against pancreatic adenocarcinomas

References

• Chen L-C, Chen Y-C, Su C-Y, et al. (2016). Development and characterization of self-assembling lecithin-based mixed polymeric micelles containing quercetin in cancer treatment and an in vivo pharmacokinetic study. Int J Nanomed 11:1557.
   PubMed Web of Science ®Google Scholar
• Cho Y-A, Choi J-S, Burm J-P. (2011). Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. Pharmacol Rep 63:1066–73.
   PubMed Web of Science ®Google Scholar
• Cole C, Fuller R, Mallet A, Rowland I. (1985). The influence of the host on expression of intestinal microbial enzyme activities involved in metabolism of foreign compounds. J Appl Bacteriol 59:549–53.
   PubMedGoogle Scholar
• Drengler RL, Kuhn JG, Schaaf LJ, et al. (1999). Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17:685–96.
   PubMed Web of Science ®Google Scholar
• Femke M, Goey AK, van Schaik RH, et al. (2018). Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet 57:1229–54.
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Mori M. (1997). Influence of various bile salts on ββ‐glucuronidase activity of intestinal bacteria. Lett Appl Microbiol 25:95–7.
   PubMed Web of Science ®Google Scholar
• Goodin S. (2007). Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions. Am J Health Syst Pharm 64:S15–S24.
   PubMed Web of Science ®Google Scholar
• Haaz M-C, Rivory LP, Riché C, Robert J. (1997). The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol 356:257–62.
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Cheshire PJ, Hallman JD, et al. (1995). Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393–403.
   PubMed Web of Science ®Google Scholar
• Jin X, Zhang Z-H, Sun E, et al. (2013). A novel drug–phospholipid complex loaded micelle for baohuoside I enhanced oral absorption: in vivo and in vivo evaluations. Drug Dev Ind Pharm 39:1421–30.
   PubMed Web of Science ®Google Scholar
• Kong R, Liu T, Zhu X, et al. (2014). Old drug new use-amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. Clin Cancer Res 20:3521–30.
   PubMed Web of Science ®Google Scholar
• Kuhn JG. (1998). Pharmacology of irinotecan. Oncology 12:39–42.
   PubMed Web of Science ®Google Scholar
• Lawrence MJ, Rees GD. (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Delivery Rev 45:89–121.
   PubMed Web of Science ®Google Scholar
• Li C, Kim M, Choi H, Choi J. (2011). Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein. Arch Pharm Res 34:1965–72.
   PubMed Web of Science ®Google Scholar
• Lin H-L, Chen L-C, Cheng W-T, et al. (2020). Preparation and characterization of a novel swellable and floating gastroretentive drug delivery system (sfGRDDS) for enhanced oral bioavailability of nilotinib. Pharmaceutics 12:137.
   PubMed Web of Science ®Google Scholar
• Lin L-C, Wang M-N, Tsai T-H. (2008). Food–drug interaction of (−)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. Chem Biol Interact 174:177–82.
   PubMed Web of Science ®Google Scholar
• Lin S-F, Chen Y-C, Ho H-O, et al. (2013). Development and characterization of dilutable self-microemulsifying premicroemulsion systems (SMEPMS) as templates for preparation of nanosized particulates. Int J Nanomed 8:3455–66.
   PubMed Web of Science ®Google Scholar
• Lin Y-M, Wu J-Y, Chen Y-C, et al. (2011). In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate. Int J Nanomed 6:2445–57.
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, Van Alphen RJ, Verweij J, et al. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182–94.
   PubMed Web of Science ®Google Scholar
• Mirkov S, Komoroski BJ, Ramírez J, et al. (2007). Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos 35:228–33.
   PubMed Web of Science ®Google Scholar
• Nabekura T, Yamaki T, Ueno K, Kitagawa S. (2008). Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother Pharmacol 62:867–73.
   PubMed Web of Science ®Google Scholar
• Negi LM, Tariq M, Talegaonkar S. (2013). Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation. Colloids Surf B Biointerfaces 111:346–53.
   PubMed Web of Science ®Google Scholar
• Pouton CW. (2000). Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci 11:S93–S8.
   PubMed Web of Science ®Google Scholar
• Rivory LP, Robert J. (1995). Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36:176–9.
   PubMed Web of Science ®Google Scholar
• Rothenberg ML. (1998). Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 25:39–46.
   PubMed Web of Science ®Google Scholar
• Schoemaker NE, Kuppens I, Huinink WWTB, et al. (2005). Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemother Pharmacol 55:263–70.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. (2013). Cancer statistics, 2013. CA Cancer J Clin 63:11–30.
   PubMed Web of Science ®Google Scholar
• Slatter JG, Schaaf LJ, Sams JP, et al. (2000). Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following iv infusion of [14C] CPT-11 in cancer patients. Drug Metab Dispos 28:423–33.
   PubMed Web of Science ®Google Scholar
• Soepenberg O, Dumez H, Verweij J, et al. (2005). Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 11:1504–11.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Van Asperen J, Mayer U, et al. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031–5.
   PubMed Web of Science ®Google Scholar
• Sperker B, Backman JT, Kroemer HK. (1997). The role of β-glucuronidase in drug disposition and drug targeting in humans. Clin Pharmacokinet 33:18–31.
   PubMed Web of Science ®Google Scholar
• Stewart CF, Zamboni WC, Crom WR, Houghton PJ. (1997). Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother Pharmacol 40:259–65.
   PubMed Web of Science ®Google Scholar
• Su C-Y, Liu J-J, Ho Y-S, et al. (2018). Development and characterization of docetaxel-loaded lecithin-stabilized micellar drug delivery system (LsbMDDs) for improving the therapeutic efficacy and reducing systemic toxicity. Eur J Pharm Biopharm 123:9–19.
   PubMed Web of Science ®Google Scholar
• Takasuna K, Hagiwara T, Hirohashi M, et al. (1996). Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752–7.
   PubMed Web of Science ®Google Scholar
• Thompson J, Zamboni WC, Cheshire PJ, et al. (1997). Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 8:313–22.
   PubMed Web of Science ®Google Scholar
• Tu J-H, Hu D-L, Dai L-L, et al. (2010). Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Xenobiotica 40:393–9.
   PubMed Web of Science ®Google Scholar
• van Erp NP, Baker SD, Zhao M, et al. (2005). Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 11:7800–6.
   PubMed Web of Science ®Google Scholar
• Veltkamp SA, Thijssen B, Garrigue JS, et al. (2006). A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 95:729–34.
   PubMed Web of Science ®Google Scholar
• Yang F-H, Zhang Q, Liang Q-Y, et al. (2015). Bioavailability enhancement of paclitaxel via a novel oral drug delivery system: paclitaxel-loaded glycyrrhizic acid micelles. Molecules 20:4337–56.
   PubMed Web of Science ®Google Scholar
• Yang J, Peng R, Kong R, Yu J. (2001). Effects of 18 alpha-glycyrrhizic acid on rat liver cytochrome P450 isoenzymes and phase II transferase. Yao Xue Xue Bao 36:321–4.
   PubMedGoogle Scholar
• Yang S, Gursoy RN, Lambert G, Benita S. (2004). Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 21:261–70.
   PubMed Web of Science ®Google Scholar
• Yoshida N, Koizumi M, Adachi I, Kawakami J. (2006). Inhibition of P-glycoprotein-mediated transport by terpenoids contained in herbal medicines and natural products. Food Chem Toxicol 44:2033–9.
   PubMed Web of Science ®Google Scholar
• Younis IR, Malone S, Friedman HS, et al. (2009). Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. Cancer Chemother Pharmacol 63:517–24.
   PubMed Web of Science ®Google Scholar
• Yuan JS, Ansari M, Samaan M, Acosta EJ. (2008). Linker-based lecithin microemulsions for transdermal delivery of lidocaine. Int J Pharm 349:130–43.
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Houghton PJ, Thompson J, et al. (1998). Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin Cancer Res 4:455–62.
   PubMed Web of Science ®Google Scholar